The International Congress of Hyperthermic Oncology (ICHO) is a quadrennial event bringing together the annual gatherings of the Society of Thermal Medicine (STM), European Society of Hyperthermic Oncology (ESHO) and the Asian Society of Hyperthermic Oncology (ASHO) to a common venue. Clinicians and Researchers from around the world gather to share their findings on the effect of hyperthermia (heat) as a weapon in the fight against cancer.
At this event, Pyrexar was honored to present its Lifetime Achievement Award to individuals whose contributions to the field have directly affected the survival of those with life-threatening cancer.
The first recipient of the Pyrexar LTA award is Paul Turner, considered the father of phased array radiofrequency hyperthermia. Holder of multiple patents in the arena of thermal therapy, Paul has been working in the field for almost 40 years, and his contributions to cancer therapies are realized in the entire Pyrexar Medical product line.
The second recipient, Gerhard Sennewald, Ph.D., is the president of Sennewald Medizintechnik GmbH in Munich, Germany. A long-time board member of the former BSD Medical and current Pyrexar Medical. His relationships with the European cancer treatment community and his team of engineers are instrumental in the development of Image-Guided Thermal Therapy. IGTT uses Magnetic Resonance Imaging to determine tumor core temperature to guide the application of hyperthermia in the treatment of cancer.
"We are so fortunate to have these gentlemen associated with Pyrexar," says Mark Falkowski, CEO. "Their integrity, focus, and passion have given the world a technology that is for the greater good.” We look forward to future contributions toward the development of new, innovative, and exciting technologies in the fight against cancer.